Intranasal Therapeutic Cell Delivery Bypassing Blood-Brain Barrier
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering therapeutic cells and regulatory agents to the central nervous system (CNS) are invasive and inefficient, as they often require systemic administration or invasive techniques that do not effectively target damaged areas, and many substances fail to cross the blood-brain barrier.
Innovation Solution
A method involving the intranasal application of therapeutic cells and pharmaceutical compositions to the upper third of the nasal cavity, utilizing a neural pathway to bypass the blood-brain barrier, accompanied by antibiotics and immunosuppressive agents to enhance delivery and viability, and regulatory agents to promote cell survival and differentiation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic administration or invasive techniques are used to deliver therapeutic cells to the CNS, then delivery can be achieved, but the procedure becomes invasive and substances fail to effectively target damaged areas due to the blood-brain barrier
Solution Approach 1:
The patent uses the nasal cavity and olfactory neural pathway as an intermediary route to deliver therapeutic cells to the CNS. Instead of directly crossing the blood-brain barrier through systemic administration, the composition travels through the nasal mucosa and along olfactory nerves to reach the brain, bypassing the barrier without requiring invasive procedures
Solution Approach 2:
The patent replaces the mechanical/invasive approach of surgical delivery with a physiological pathway utilizing the nasal cavity and olfactory system. The delivery mechanism shifts from forced invasive insertion to natural physiological transport routes that the body already possesses
2Reliability
If systemic administration is used to deliver therapeutic agents to the CNS, then broad distribution is achieved, but targeted delivery to damaged areas is inefficient and systemic exposure increases
Solution Approach 1:
The patent applies local quality by directing the therapeutic composition specifically to the upper third of the nasal cavity, which corresponds to the olfactory region. This localized application ensures that the therapeutic cells are funneled through the olfactory neural pathway to specific brain regions, achieving targeted delivery rather than broad systemic distribution
Solution Approach 2:
The patent segments the delivery pathway into distinct anatomical regions: the upper third of the nasal cavity for application, the olfactory neural pathway for transport, and specific CNS target areas for delivery. This segmentation allows precise routing of the therapeutic composition to damaged areas while minimizing exposure to other systemic regions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for non-invasive, targeted delivery of therapeutic cells and agents directly to the CNS, improving clinical outcomes for neurological conditions by enhancing cell survival, differentiation, and regeneration, while minimizing systemic exposure and invasive procedures.
Implementation Method 1
A method involving the intranasal application of therapeutic cells and pharmaceutical compositions to the upper third of the nasal cavity, utilizing a neural pathway to bypass the blood-brain barrier
Data Source
AI summary
Methods and compositions for preventing and treating the damaged and/or degenerating CNS experiencing loss or death of CNS cells. Various embodiments of the invention transport a therapeutically effective amount of, inter alia at least one therapeutic cell to the CNS by intranasal application to the upper-third of the nasal cavity, thereby bypassing the blood-brain barrier. A pharmaceutical composition according to the invention may comprise at least one therapeutic cell, at least one delivery-enhancement agent, at least one antibiotic, at least one regulatory factor and/or at least one immunosuppressive agent, wherein the composition is delivered to the upper-third of the nasal cavity. The therapeutic cells, once delivered to the CNS, migrate preferentially to the area of damage or degeneration or injury.